BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 30557850)

  • 21. Vandetanib: a novel targeted therapy for the treatment of metastatic or locally advanced medullary thyroid cancer.
    Ton GN; Banaszynski ME; Kolesar JM
    Am J Health Syst Pharm; 2013 May; 70(10):849-55. PubMed ID: 23640345
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Selective use of vandetanib in the treatment of thyroid cancer.
    Fallahi P; Di Bari F; Ferrari SM; Spisni R; Materazzi G; Miccoli P; Benvenga S; Antonelli A
    Drug Des Devel Ther; 2015; 9():3459-70. PubMed ID: 26170630
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Primary Adrenal Insufficiency During Lenvatinib or Vandetanib and Improvement of Fatigue After Cortisone Acetate Therapy.
    Colombo C; De Leo S; Di Stefano M; Vannucchi G; Persani L; Fugazzola L
    J Clin Endocrinol Metab; 2019 Mar; 104(3):779-784. PubMed ID: 30383218
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Vandetanib and the management of advanced medullary thyroid cancer.
    Campbell MJ; Seib CD; Gosnell J
    Curr Opin Oncol; 2013 Jan; 25(1):39-43. PubMed ID: 23202050
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Vandetanib, in the management of patients with locally advanced or metastatic medullary thyroid carcinomas].
    Chougnet CN; Schlumberger M; Leboulleux S; Baudin E
    Bull Cancer; 2014 Sep; 101(9):891-5. PubMed ID: 25296193
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Vandetanib in children and adolescents with multiple endocrine neoplasia type 2B associated medullary thyroid carcinoma.
    Fox E; Widemann BC; Chuk MK; Marcus L; Aikin A; Whitcomb PO; Merino MJ; Lodish M; Dombi E; Steinberg SM; Wells SA; Balis FM
    Clin Cancer Res; 2013 Aug; 19(15):4239-48. PubMed ID: 23766359
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Vandetanib for the treatment of medullary thyroid carcinoma.
    Cooper MR; Yi SY; Alghamdi W; Shaheen DJ; Steinberg M
    Ann Pharmacother; 2014 Mar; 48(3):387-94. PubMed ID: 24259657
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Vandetanib: too dangerous in medullary thyroid cancer.
    Prescrire Int; 2012 Oct; 21(131):233. PubMed ID: 23185843
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sorafenib in Japanese Patients with Locally Advanced or Metastatic Medullary Thyroid Carcinoma and Anaplastic Thyroid Carcinoma.
    Ito Y; Onoda N; Ito KI; Sugitani I; Takahashi S; Yamaguchi I; Kabu K; Tsukada K
    Thyroid; 2017 Sep; 27(9):1142-1148. PubMed ID: 28635560
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Body composition variation and impact of low skeletal muscle mass in patients with advanced medullary thyroid carcinoma treated with vandetanib: results from a placebo-controlled study.
    Massicotte MH; Borget I; Broutin S; Baracos VE; Leboulleux S; Baudin E; Paci A; Deroussent A; Schlumberger M; Antoun S
    J Clin Endocrinol Metab; 2013 Jun; 98(6):2401-8. PubMed ID: 23543666
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Vandetanib for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease: U.S. Food and Drug Administration drug approval summary.
    Thornton K; Kim G; Maher VE; Chattopadhyay S; Tang S; Moon YJ; Song P; Marathe A; Balakrishnan S; Zhu H; Garnett C; Liu Q; Booth B; Gehrke B; Dorsam R; Verbois L; Ghosh D; Wilson W; Duan J; Sarker H; Miksinski SP; Skarupa L; Ibrahim A; Justice R; Murgo A; Pazdur R
    Clin Cancer Res; 2012 Jul; 18(14):3722-30. PubMed ID: 22665903
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sorafenib for the Treatment of Progressive Metastatic Medullary Thyroid Cancer: Efficacy and Safety Analysis.
    de Castroneves LA; Negrão MV; de Freitas RM; Papadia C; Lima JV; Fukushima JT; Simão EF; Kulcsar MA; Tavares MR; Jorge AA; de Castro G; Hoff PM; Hoff AO
    Thyroid; 2016 Mar; 26(3):414-9. PubMed ID: 26701095
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Risk of rash in cancer patients treated with vandetanib: systematic review and meta-analysis.
    Rosen AC; Wu S; Damse A; Sherman E; Lacouture ME
    J Clin Endocrinol Metab; 2012 Apr; 97(4):1125-33. PubMed ID: 22378813
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and Safety of Vandetanib in Progressive and Symptomatic Medullary Thyroid Cancer: Post Hoc Analysis From the ZETA Trial.
    Kreissl MC; Bastholt L; Elisei R; Haddad R; Hauch O; Jarząb B; Robinson B; Colzani R; Foster M; Weiss R; Schlumberger M
    J Clin Oncol; 2020 Aug; 38(24):2773-2781. PubMed ID: 32584630
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term follow-up and safety of vandetanib for advanced medullary thyroid cancer.
    Ramos HE; Hecht F; Berdelou A; Borget I; Leboulleux S; Baudin E; Schlumberger M
    Endocrine; 2021 Feb; 71(2):434-442. PubMed ID: 32691271
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pazopanib, Cabozantinib, and Vandetanib in the Treatment of Progressive Medullary Thyroid Cancer with a Special Focus on the Adverse Effects on Hypertension.
    Milling RV; Grimm D; Krüger M; Grosse J; Kopp S; Bauer J; Infanger M; Wehland M
    Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30347815
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Management of treatment-related toxicities in advanced medullary thyroid cancer.
    Brose MS; Bible KC; Chow LQM; Gilbert J; Grande C; Worden F; Haddad R
    Cancer Treat Rev; 2018 May; 66():64-73. PubMed ID: 29704768
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Medullary thyroid carcinoma - Adverse events during systemic treatment: risk-benefit ratio.
    Maciel LMZ; Magalhães PKR
    Arch Endocrinol Metab; 2017; 61(4):398-402. PubMed ID: 28658345
    [TBL] [Abstract][Full Text] [Related]  

  • 39. cabozantinib (COMETRIQ⁰). In medullary thyroid cancer: more harmful than beneficial, as is vandetanib.
    Prescrire Int; 2016 Jan; 25(167):11-3. PubMed ID: 26942253
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Vandetanib therapy in medullary thyroid cancer.
    Grabowski P; Briest F; Baum RP; Zaknun JJ; Kulkarni HR; Zeitz M; Hörsch D
    Drugs Today (Barc); 2012 Nov; 48(11):723-33. PubMed ID: 23170308
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.